Trial Profile
Parallel comparison of tenofovir and emtricitabine/tenofovir pre-exposure prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PartnersPrEP
- 26 Apr 2022 Results of a pooled participant-level data analysis ((iPrEx, VOICE and Partners PrEP studies) characterizing HIV-preventive, plasma tenofovir concentrations published in the Clinical Infectious Diseases
- 11 Aug 2020 According to a Gilead Sciences media release, the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF).The approval of Truvada for PrEP was supported by data from two randomized, double-blind, placebo-controlled trials known as the Pre-Exposure Prophylaxis Initiative (iPrEx) and Partners PrEP.
- 22 Aug 2016 According to a Gilead Sciences media release, the European Commission has granted marketing authorisation in the European Union (EU) for once daily Truvada (emtricitabine / tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired human immunodeficiency virus type 1 (HIV-1) infection in adults at high risk based on data from this and iPrEX (CTP 700022550) trials.